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Abstract
Fiji, an upper-middle income state in the Pacific Ocean, has experienced an increase in con-
firmed case notifications of enteric fever caused by Salmonella enterica serovar Typhi (S.
Typhi). To characterize the epidemiology of typhoid exposure, we conducted a cross-sectional
sero-epidemiological survey measuring IgG against the Vi antigen of S. Typhi to estimate the
effect of age, ethnicity, and other variables on seroprevalence. Epidemiologically relevant cut-off
titres were established using a mixed model analysis of data from recovering culture-confirmed
typhoid cases. We enrolled and assayed plasma of 1787 participants for anti-Vi IgG; 1,531 of
these were resident in mainland areas that had not been previously vaccinated against S. Typhi
(seropositivity 32.3% (95%CI 28.2 to 36.3%)), 256 were resident on Taveuni island, which had
been previously vaccinated (seropositivity 71.5% (95%CI 62.1 to 80.9%)). The seroprevalence
on the Fijian mainland is one to two orders of magnitude higher than expected from confirmed
case surveillance incidence, suggesting substantial subclinical or otherwise unreported typhoid.
We found no significant differences in seropositivity prevalences by ethnicity, which is in contrast
to disease surveillance data in which the indigenous iTaukei Fijian population are disproportion-
ately affected. Using multivariable logistic regression, seropositivity was associated with incre-
ased age (odds ratio 1.3 (95% CI 1.2 to 1.4) per 10 years), the presence of a pit latrine (OR 1.6,
95%CI 1.1 to 2.3) as opposed to a septic tank or piped sewer, and residence in settlements
rather than residential housing or villages (OR 1.6, 95% CI 1.0 to 2.7). Increasing seropositivity
with age is suggestive of low-level endemic transmission in Fiji. Improved sanitation where pit
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latrines are used and addressing potential transmission routes in settlements may reduce expo-
sure to S. Typhi. Widespread unreported infection suggests there may be a role for typhoid vac-
cination in Fiji, in addition to public health management of cases and outbreaks.
Author summary
Fiji has experienced a decade-long increase in typhoid fever cases, a potentially life-threat-
ening systemic bacterial disease caused by Salmonella Typhi. We undertook a representa-
tive blood-serum community survey to measure antibodies (IgG) against the Vi antigen
of Salmonella Typhi using a rigorous survey design. We found one in three residents of
mainland, unvaccinated Fiji had detectable antibody against Vi. This was higher than
would be expected from confirmed case notifications received by the national surveillance
system. Additionally, similar antibody responses were detected in Fijians of all ethnicities,
which contrasts to surveillance cases in which indigenous iTaukei Fijians were dispropor-
tionately affected. Serology on a Fijian island where a significant proportion of the popula-
tion has been vaccinated found that three-quarters of residents were seropositive three
years after the Vi-polysaccharide typhoid vaccination campaign. Importantly, in mainland
participants, seroprevalence increased with age, suggesting long-standing, low-level,
endemic transmission. Pit latrines were associated with seropositivity when compared
with septic tanks, and settlements compared with residential housing. Very high antibody
titres in a small percentage of participants may suggest carriage of Salmonella Typhi. The
seroprevalence findings suggest eliminating typhoid from Fiji by focussing on cases and
outbreaks alone will be challenging. Our results support typhoid vaccination and further
development of water, sanitation and hygiene infrastructure in Fiji.
Introduction
Typhoid fever is a systemic disease resulting from infection by the bacterium Salmonella enterica
subspecies enterica serovar Typhi (S. Typhi), a human restricted pathogen transmitted from fae-
ces to water and food or by contact and fomites. [1,2] Infection syndromes range from asymp-
tomatic (including carriage) to severe disease with life-threatening complications, including
intestinal perforation, encephalopathy, and haemodynamic shock [3,4]. Many typhoid cases
present as non-specific acute febrile illnesses that may be difficult to differentiate from other
common tropical infectious diseases such as dengue and leptospirosis. There were an estimated
11.9 million (9.9 to 14.7) cases of typhoid in low and middle income countries in 2010, resulting
in 129,000 (75,000 to 208,000) deaths [5].
Fiji is an upper middle income country with an estimated population of 892,000 in 2015 [6]
across 100 inhabited Pacific Ocean islands, predominantly residing on Viti Levu and Vanua
Levu [7]. Administratively, Viti Levu comprises the Western and Central Divisions, the latter
containing the capital Suva. Northern Division comprises of Vanua Levu and Taveuni island,
whilst Eastern Division comprises of smaller island groups.
Phylogenetic evidence from genome sequencing suggests that S. Typhi has a long history in
Fiji though notified blood-culture confirmed cases numbered fewer than 30 annually up to
2004 [8,9]. Annual blood-culture confirmed cases notified through Divisional hospitals to
national surveillance have risen [9,10], from 4.4 cases per 100,000 population in 2004 to 45
cases per 100,000 during 2008–2011 [11]. Northern Division saw 121 cases per 100,000 in 2009
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vs 28 per 100,000 in the West and 19 per 100,000 in Central [11]. A proportionate increase in
clinically diagnosed typhoid was also reported [12].
Notably, >90% of blood-culture confirmed cases are reported amongst indigenous Fijians
(iTaukei, approximately 57% of the population), with few cases reported in Fijians of Indian
descent (Indo-Fijians, 38% of the population) or Fijians of Asian or European descent[12].
The causes of this disparity are unknown [12]; health seeking behaviours would be expected to
lead to higher relative ascertainment in Indo-Fijians than iTaukei [13].
Historically subsistent through agriculture and fishing, more than half the population now
reside in urban areas, including informal settlements close to riverbanks and other flood-
prone areas with limited access to water and sanitation infrastructure [14].
Typhoid vaccine is not routinely used in Fiji; however, in 2010, following cyclone Tomas, a Vi-
polysaccharide (Vi-PS) vaccination campaign was conducted in the highest incidence areas of
Fiji. These were predominantly in the Northern Division, with high coverage on Taveuni island
and in the Cakaudrove subdivision on Vanua Levu, with targeted geographical vaccination within
subdivisions elsewhere [11] reaching 64,000 people, 8% of the national population. Observed dis-
ease incidence rates declined in the targeted areas against increasing or stable rates in other areas
[11]. Given the ongoing typhoid transmission and the short duration of Vi-PS protection,[15] a
2012 expert meeting was convened by the Ministry of Health, with Australian Aid support, to
“develop, prioritise and implement a comprehensive control and prevention strategy” [12].
Knowledge gap analysis identified that a serological survey could inform vaccination policy [12].
Seroepidemiological surveys can help determine population immunity, pathogen exposure
and susceptibility, as well as disease- and exposure-related risk factors [16]. Conducted alongside
clinical and/or laboratory surveillance, seroepidemiology can help quantify surveillance under-
or over-ascertainment, including for enteric diseases [17–20]. Typhoid transmission dynamics
are influenced by setting-specific immunity and carriage [21–23]; however, the seroepidemiolo-
gical methods to attain these are underexploited [17]. This may be in part due to concerns about
the sensitivity and specificity of serology for typhoid, which historically has not demonstrated
sufficient discriminatory power for individual-level clinical diagnosis [24], (though recent meth-
ods may offer promise [25]) as well as concerns about the specificity of assays for carriage detec-
tion [26–28] and the existence of multiple immunological pathways to immunity against
typhoid fever [29]. Serosurveys utilising assays based on purified, pharmaceutical-grade Vi poly-
saccharide, the “virulence” factor expressed by S. Typhi [27], for detection of anti-Vi IgG anti-
body may offer a more reliable approach by avoiding cross-reactivity that arises when Vi antigen
preparations contain other bacterial antigens [30,31]. Furthermore, high anti-Vi titres may indi-
cate prolonged immune stimulus from chronic carriage [30,32–34]. We undertook a joint
typhoid and leptospirosis seroepidemiological survey [35], and present typhoid findings here.
Methods
Ethics statement
The study was approved by the Fiji National Research Ethics Review Committee (2013–03)
and the London School of Hygiene & Tropical Medicine observational study research ethics
committee (6344). All adult participants provided written informed consent. Parents/guard-
ians provided written informed consent on behalf of all child participants (under the age of 18
years old). Written assent was also provided by children aged 12 years and above.
Study design
To characterize the immunoepidemiology of typhoid infection in Fiji, with the aim of inform-
ing effective and efficient control measures, we surveyed three groups of people: group 1)
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unvaccinated areas of the main Fijian islands; 2) residents of Taveuni island, where a high-cov-
erage vaccination campaign was done in 2010 [11]; and group 3) a cohort of convalescing
Fijian culture-confirmed typhoid cases, to enable estimation of a threshold for seropositivity.
Sampling methods. Group 1, Mainland: Sixty-four community clusters were randomly
selected by multi-stage, cross-sectional sampling on Viti Levu and Vanua Levu and visited for
serological sampling and risk factor questionnaire interviews [36–50] from September to
December 2013. Vaccinated areas were excluded to avoid confounding of interpretation of
serological responses to natural exposure. Eastern Division (population <40,000) [13], was
excluded for logistical reasons. Group 2, Taveuni: A vaccination campaign on Taveuni Island
in 2010 achieved 92% coverage [11]; 11 community clusters were randomly selected by multi-
stage sampling as vaccinated comparators and surveyed in September 2013. Group 3, Conva-
lescent cases: Sequential recently blood-culture confirmed typhoid cases in the Central Divi-
sion were identified from national surveillance and hospital records and approached to seek
informed consent for blood sampling. Further blood-culture confirmed cases diagnosed previ-
ously were identified during visits to the cases’ villages or residences and invited to participate
after validation with national surveillance records. Between November 2013 and April 2014 up
to three convalescent blood samples were collected at minimum one-month intervals.
Headmen, health workers and other community leaders were visited to seek agreement to
participate and arrange visiting with the full study team. No communities declined participa-
tion. A team of experienced, multilingual Fijian field workers was trained and questionnaires
piloted. Interviews were conducted in iTaukei, English or Hindi at the preference of the inter-
viewee. Trained phlebotomists collected venous blood samples.
For group 1, cluster numbers per administrative Division were proportional to the resident
typhoid non-immunised population. Contiguous nursing zones serving approximately 1,000
to 10,000 people were selected with probability proportional to population size [51] by random
number generation using Ministry of Health administrative records. Community clusters
were randomly selected within selected nursing zones from unweighted lists, in the absence of
detailed population data.
Households were randomly selected within each community and an occupant aged1 year
was randomly selected (to reduce correlation compared with recruiting multiple residents)
using random number tables. Health registries were used for this sampling where available;
Otherwise, in rural village-like clusters, Expanded Programme on Immunization-derived sam-
pling of houses was conducted in randomly selected directions (by pen-spin) from community
centre points [52]. For street clusters, random starting points and set sampling intervals were
determined following rapid house enumeration.
Household occupancy was de facto previous night residency as per Fiji census methods.
Study information was provided. All adult participants provided written informed consent.
Parents/guardians provided written informed consent on behalf of all child participants
(under the age of 18 years old). Written assent was also provided by children aged 12 years and
above. Exclusion criteria were clotting disorders, medical anticoagulation or severe medical
disorders that would preclude safe participation.
For group 1 residents in Viti Levu, age- stratified sampling (strata size proportional to
national population) was used for representativeness across age groups after field data review
identified potential age imbalances in some clusters on Vanua Levu and Taveuni. If the
selected participant was temporarily absent from a house e.g. for work or school, data collec-
tors revisited later in the day after their expected time of return. If a whole household was
absent, an alternative house was randomly selected from the health registry, or by geographical
proximity.
Seroepidemiological survey of typhoid in Fiji
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Sample size
A sample size of 1,600 was proposed for group 1, giving for 7% seroprevalence confidence
intervals (CI) for age band groups of 200, if seroprevalence was 40%, at alpha = 0.05. If age
bands had design effect of two due to non-independence within clusters, CI would be suffi-
ciently precise at 10%. Expected seroprevalence levels were informed by prior work on
Taveuni (Eric Nilles, data on file).
Laboratory methods
Enzyme-linked immunosorbent assays (ELISAs) to detect S. Typhi Vi-polysaccharide antigen-
specific IgG in human serum samples were performed as described previously [53] (provided
by Sclavo Behring Vaccines Institute for Global Health, Siena, Italy). Briefly, ELISA plates were
coated overnight with 1μg/ml of Vi polysaccharide antigen. Coated plates were washed and
blocked with 5% fat-free milk solution. Following blocking, plates were washed and incubated
with serum diluted at 1:200 at room temperature (RT) for 2 hours. Plates were washed and
incubated with secondary antibody, alkaline phosphatase-conjugated anti-human IgG at RT
for one hour. Finally, p-Nitrophenyl phosphate (SigmaFAST N1891, Sigma-Aldrich, United
Kingdom) substrate was added for 30 minutes at RT and absorbance was read at dual wave-
lengths (405 nm and 490 nm) using an automated microplate reader (Biorad). Optical densi-
ties (OD) from blank control wells were subtracted from all sample absorbance values prior to
estimation of serum titers from a standard curve. We selected 96 random Fijian plasma sam-
ples and subjected them to the anti-Vi ELISA. Twenty samples of these samples (with an OD
>2.5) were pooled (standard plasma) and used to generate a standard curve. One ELISA Unit
(EU) was defined as the reciprocal of the standard dilution (made by 10 2-fold dilutions of the
standard plasma) that gave an absorbance value equal to 1 in this assay. All samples were tested
at the Oxford University Clinical Research Unit in Ho Chi Minh City, Vietnam.
Data analysis
A surveillance seropositivity threshold was determined using a mixed effects model of serial
titres in the convalescent cases group. Models were fitted by maximum likelihood estimation
(ML), using a random-intercept fixed-slope above a threshold value and random intercept
time-invariant model below, signifying antibody returning to a baseline level. Data from two
patients with titres at the upper limit of detection (25,000 EU) were excluded leaving 70 titres
from 28 patients. Thresholds were compared using Akaike’s information criterion (AIC).
Data were entered in EpiData 3.1 [54] and analysed in R 3.3 [55]. Seroprevalences were cal-
culated using intra-cluster correlation coefficients (ICCs) and design effects determined on log
titres with clustering at the primary sample unit. Putative risk factors for seropositivity were
estimated with Huber-White robust standard errors, clustered on the same, using the “rms”
package[56]. A multivariable model was developed from univariable risk factors with p-values
of less than 0.25, after-regrouping sparse cells for numerical stability, using a backward step-
wise approach fitted by AIC, with deletion of observations with missing data. Potential collin-
earity was assessed by linear-adjusted generalized variance inflation factors (GVIF) in the
“CAR” package [57,58], and variables were removed if GVIF^(1/(2Df)) was over 2 and not
considered epidemiologically important to retain. Data were considered insufficient to exam-
ine possible risk factors associated with titres that may indicate typhoid carriage. For compari-
son to age-based seroprevalence, typhoid fever cumulative incidence expected across the life-
course was estimated with binomial confidence intervals from confirmed cases notified in
2008–2014 to the national surveillance system at the Fiji Centre for Communicable Disease
Control, Mataika House, Suva.
Seroepidemiological survey of typhoid in Fiji
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Results
Group 1: Sixty-four mainland clusters in unvaccinated areas of Viti Levu and Vanua Levu
were visited for this sero-survey (Fig 1). Of 1,565 people approached, five declined and 1,560
were enrolled. There were no exclusions on medical grounds. A serum IgG titre against Vi
polysaccharide (anti-Vi IgG) could not be attained for 29 participants (median age 23, IQR 6
to 34; 19/29 female; 25/29 iTaukei) but was determined in 1,531 individuals (98%; age range 1
to 85 years, median 29, IQR 16 to 48; 820/1,530 (54%) female; 1,164/1,530 76%) iTaukei; see
Table 1; non-responses excluded).
For Group 2, on Taveuni Island, the location for a vaccination campaign, 277 people were
approached and 256 participants (127 (49.6%) female) in 11 clusters enrolled, with nil excluded.
All provided samples that were successfully assayed for anti-Vi IgG (Table 2 and Fig 1).
Group 3: Thirty-seven patients with recent blood-culture confirmed typhoid provided one
or more samples that were assayed for anti-Vi IgG (19 (51.4%) female, median age 30, IQR 14
to 42) (Table 3); 30 provided two or more blood samples; and 19 provided three samples.
Median duration from reported fever onset to first sample collection was 187 days (IQR 132 to
272 days).
Mixed model seropositivity threshold estimation in Group 3 (convalescent typhoid cases)
exhibited best fit at 64 EU (S1 Fig and S1 Table). The ICC and design effect per Group 1
Fig 1. Administrative Divisions and Cluster sites on mainland Fiji (Viti Levu and Vanua Levu) and Taveuni islands.
https://doi.org/10.1371/journal.pntd.0005786.g001
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Table 1. Group 1. Demographics of mainland Viti Levu and Vanua Levu (unvaccinated areas) survey
participants.
Variable Value
Number of participants assayed 1531
Age (median, IQR) 29 (16–48)
1 to 14 343 (224%)
15–34 554 (362%)
35–54 384 (251%)
55+ 250 (229%)
Female 820 (536%)
Clusters 64
Central Division 28
Northern Division 11
Western Division 25
Participants per cluster (SD) 239 (25)
iTaukei 1164 (761%)
Indo-Fijian 338 (221%)
Other 28 (18%)
House income <100 FJD/wk 548 (36.3%)
100–199 490 (32.5%)
200–299 296 (19.6%)
300–399 61 (4.0%)
400+ 81 (5.4%)
Self-report previous vaccination against typhoid 103 (6.7%)
Self-report previous typhoid fever 20 (1.3%)
https://doi.org/10.1371/journal.pntd.0005786.t001
Table 2. Group2. Demographics of Taveuni island (Vi-polysaccharide vaccinated area) survey participants.
Variable Value
Number of participants assayed 256
Age (median, IQR) 36 (24 to 52)
1 to 14 32 (12.5%)
15–34 90 (35.3%)
35–54 85 (33.3%)
55+ 48 (18.8%)
Female 127 (50%)
Clusters 11
Participants per cluster (SD) 23.3 (3.3)
iTaukei 220 (86.3%)
Indo-Fijian 27 (10.6%)
Other 8 (3.1%)
House income <100 FJD/wk 91 (36.5%)
100–199 99 (39.8%)
200–299 22 (8.8%)
300–399 12 (4.8%)
400+ 14 (5.6%)
Self-report previous vaccination against typhoid 54 (21.1%)
Self-report previous typhoid fever 5 (2.0%)
https://doi.org/10.1371/journal.pntd.0005786.t002
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mainland cluster were 0.09 and 3.03, respectively. Across the five-year age bands (S2 Table),
the Group 1 mean ICC and design effect were 0.13 and 1.09, respectively.
At the 64 EU threshold, 32.3% of Group 1 mainland participants (95%CI 28.2 to 36.3%)
were seropositive for anti-Vi IgG (S3 Table), compared to 71.5% (95% CI 62.1% to 80.9%) of
Group 2 (Taveuni island). For sensitivity analysis, at a threshold of 100 EU, 177% of the
Group 1 mainland participants (95%CI 144 to 21.0%) were seropositive, and 58.6% (95% CI
48.4% to 68.8%) of Group 2 (Taveuni island) (S3 Table). To determine a rough estimate of car-
riage prevalence within Group 1 (mainland), we examined those with the highest anti-Vi IgG
titres; 2.8% (14 to 42%) of the sampled population had an antibody titre of 500 EU or above
and 1.4% (0.4% to 24%) of the sampled population had an antibody titre of 1,000 EU or above
(S3 Table).
The anti-Vi IgG titre distributions are shown in Fig 2 for each surveyed group. The distri-
bution of antibody titres in group 2 (Taveuni island) was shifted rightward relative to the
Group 1 (mainland) titres, as would be predicted with the mass administration of Vi-PS vac-
cine on Taveuni. Thirty-nine (15%, 11.2 to 20.4%) of the 256 Group 2 (Taveuni) participants
had Vi IgG titres at the upper limits of detection. In group 3, the convalescent typhoid cases,
titres were bimodal, with the higher peak above the modal titre for the mainland group.
Age trends for unvaccinated iTaukei and non-iTaukei ethnic groups each showed increas-
ing seroprevalence with age at 64 EU threshold (group 1 mainland; Fig 3). These increased
from approximately 20% in the youngest age bands to 50% in the oldest. In sensitivity analysis
at 100 EU threshold, age and ethnicity trends were comparable, with seroprevalence rising
from <10% in younger groups to approximately 30% in the oldest age brackets. Notably, for
each ethnic group, seroprevalence by age band was substantially higher than the equivalent
cumulative incidence that would arise if considering only confirmed cases, more than ten-fold
in iTaukei Fijians and several hundred-fold in non-iTaukei Fijians.
Multivariable analysis of group 1 (mainland) found several factors were significantly
associated with seropositivity at a 64 EU anti-Vi IgG threshold after adjusting for potential
confounders (Table 4). Western Division residents had an adjusted odds ratio (OR) of 0.6
(95%CI 0.4 to 0.8) for seropositivity in comparison to the Central Division. Age association
with seropositivity was retained, with an adjusted OR of 1.3 (95% CI 1.2 to 1.4) for every
ten-year increase. Individuals with pit sewage systems had an adjusted OR of 1.6 (95% 1.1 to
2.3, p = 0.01) for seropositivity in comparison to participants with septic tanks. Residence in
a settlement rather than residential housing had an adjusted OR 1.6 (95% CI 1.0 to 2.7) for
seropositivity.
Table 3. Group3. Demographics of convalescent confirmed typhoid cases.
Variable Value
Number of participants assayed 37
Age (median, IQR) 30, 14 to 42
5 to 14 10 (27.0%)
15–34 12 (32.4%)
35–54 12 (32.4%)
55–74 3 (8.1%)
Female 19 (51.4%)
iTaukei 36 (97.3%)
Indo-Fijian 0
Other (Pacific Islander) 1 (2.7%)
https://doi.org/10.1371/journal.pntd.0005786.t003
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After adjustment, no significant association with seropositivity was observed at p<0.05 for
ethnicity, community type, rural residence, self-reported typhoid vaccination, or self-reported
diagnosis of typhoid fever. “Home toilet type” was excluded from consideration for multivari-
able analysis: pour-flush (water seal) toilets were found to be associated with seropositivity on
univariable analysis, however these are installed in response to disease outbreaks and so are
confounded by indication (Fiji National Taskforce on Control of Outbreak-Prone Diseases,
Fig 2. Distributions of log10 anti-Vi IgG antibody titres in A) Group 1: residents of Fiji mainland Viti Levu and Vanua Levu islands; B) Group 2:
residents of Taveuni island, where a vaccination campaign with Vi-polysaccharide injection was conducted three years previously; and C)
Group 3: recovering cases of culture-confirmed typhoid. Red vertical line denotes 64 ELISA unit seropositivity threshold determined from case
antibody kinetic analysis; blue line denotes 100 ELISA unit threshold used in sensitivity analysis. Case titres are mean log titre if multiple
samples collected, range 68 to 645 days from fever onset.
https://doi.org/10.1371/journal.pntd.0005786.g002
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personal communication 2015). Other candidate risk factors identified on univariable screen-
ing (S4 Table) were not retained in the final model, including sex, drinking water sources,
Fig 3. Seroprevalence of anti-Vi IgG by age and ethnicity (iTaukei and non-iTaukei) at A) 64 ELISA units (case-fitted threshold) and B) 100 ELISA units
(sensitivity analysis). Each panel also indicates confirmed case cumulative incidence by ethnicity. Shared areas denote 95% confidence intervals.
https://doi.org/10.1371/journal.pntd.0005786.g003
Table 4. Risk factors by adjusted odds ratios for anti-Vi IgG seropositivity at 64 ELISA units for mainland Viti Levu and Vanua Levu by cluster-
robust multivariable logistic regression.
Variable Value OR 95% CI p-value
Division or island Central Division Baseline
Western Division 0.58 0.41 to 0.83 0.0027 **
Vanua Levu 0.74 0.46 to 1.17 0.19
Age Per decade 1.31 1.23 to 1.40 <0.0001 ***
Ethnicity Other vs iTaukei 0.79 0.54 to 1.14 0.21
Community type Residential
Village 1.07 0.61 to 1.89 0.82
Settlement 1.63 1.00 to 2.65 0.048 *
Rurality Urban baseline
Peri-urban 0.65 0.41 to 1.01 0.055
Rural 1.17 0.72 to 1.88 0.53
Home sewage Septic tank Baseline
Piped sewer 1.07 0.77 to 1.48 0.69
Pit 1.62 1.12 to 2.32 0.01 *
Elsewhere 0.82 0.39 to 1.72 0.60
Typhoid vaccination self-report Yes 1.34 0.91 to 1.96 0.14
Typhoid diagnosed, self-report Yes 1.66 0.77 to 3.50 0.18
*p<0.05
**p<0.01
***p<0.001
n = 1436 complete records
https://doi.org/10.1371/journal.pntd.0005786.t004
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kava consumption, bathing or washing in rivers and typhoid cases within the household or
social network.
Discussion
This seroepidemiological survey found seroprevalence of IgG against the Vi antigen of S.
Typhi of 32.3% (95%CI 28.2 to 36.3%) in mainland Fiji: one to two orders of magnitude higher
than would be predicted from case notifications. Seroprevalence increased with age, suggesting
established endemic transmission. Both iTaukei and non-iTaukei ethnic groups exhibit similar
seroprevalences across age groups, in contrast to notified disease, disproportionately reported
from iTaukei Fijians. Some very high titres suggest that carriage occurs. The higher anti-Vi
seroprevalence from Vi-PS vaccinated settings also informs the use of anti-Vi IgG as a surveil-
lance marker in unvaccinated populations.
Our population-representative survey design strengthens external validity of seroprevalence
estimates over convenience sampling, particularly for age-based inference, as children are
rarely blood donors or inpatients. A limitation is the use of a single antigen due to resource
availability, mitigated by mixed model determination of a surveillance titre threshold.
The proportion non-iTaukei (24%, specifically Indo-Fijian (22%)), was lower than expected
from census data [13]. Potentially a greater proportion of Indo-Fijians reside in larger commu-
nities within nursing zones than documented in the sampling frame, or in vaccinated areas;
higher emigration and lower fertility rates may also contribute [13]. Post-stratification weight-
ing was not considered appropriate given demographic trend uncertainties since the 2007 cen-
sus and sparse sub-nursing zone population records. Representativeness was addressed
through survey design, and clustering through design-effects (which were modest) and clus-
ter-robust regression. The slight excess of females in the survey may be due to different resi-
dency patterns, such as male overnight residency in agricultural shelters.
Vi IgG titres can be compared across studies, despite incomplete international assay stan-
dardisation [59]. The Fiji results contrast to two Vi ELISA serosurveys from Kathmandu,
Nepal. The first found rising serum bactericidal activity with age, suggesting a similar acquisi-
tion of exposure with age, but found no age trend in anti-Vi IgG. [60] The second, using an
assay similar to that applied in Fiji, reported high anti-Vi IgG in all age groups, suggesting
hyperendemicity [61]. In Cape Town, South Africa, where typhoid was considered endemic,
40% of sampled unvaccinated 9 year olds were found to have anti-Vi IgG titres believed to be
protective [62]. In contrast, we found mean seroprevalence in Fijian 5 to 9 and 10 to 14 year
olds was not more than 20% (Fig 3) suggesting a lower force of infection, if antibody thresholds
are comparable. This would also be consistent with lower confirmed case incidence [12,62].
Incomplete seroconversion (as seen in other settings[63]) and waning anti-Vi IgG titres
observed amongst convalescent cases in our study suggest that multiple infections, symptom-
atic or otherwise, may be required for the establishment of sustained immunity to typhoid
fever and the corresponding seroprevalence patterns observed in the Fijian mainland group.
This concurs with prevailing conceptualisation[64,65], and experimental study [66] as well as
recent models used to estimate vaccine impact [21,67] and elucidate transmission determi-
nants in Malawi [23]. Papua New Guinea saw a similar upturn in typhoid notifications in the
1980-90s, also from a low-level, sporadic baseline, [68] with rise in population O antigen also
observed [69], suggesting an overall increase in transmission; longitudinal seroepidemiology
may likewise be informative in Fiji.
Ingestion of a large dose of S. Typhi can overwhelm naturally-acquired (and vaccine-
derived) immunity [64,66,70,71], and so age- and ethnically-differential exposure to high and
low dose inocula is one mechanism by which divergence between serological and confirmed-
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case data may be explained, if for example, iTaukei adolescents and young adults ingest larger
inocula through exposure to particular foods. Such patterns might also be compatible with
genetic differences in typhoid susceptibility, potentially mediated by HLA-type [72], with
reduced susceptibility in Fijians of Indian descent, whose South-Asian ancestors may have
experienced many millennia longer exposure to S. Typhi than iTaukei Fijians’ forebears [73–
75].
Our multivariable analysis suggest that settlement residency and pit latrines use may be risk
factors for S. Typhi infection. Whilst infrastructure upgrades may have multiple public health
benefits, typhoid prevention should be planned with consideration for findings emerging from
case-control and environmental health research [50,76]. Widespread subclinical infection,
both transient and chronic, as suggested by this serosurvey, suggests that whilst systematic
public health management of cases and outbreaks and early diagnosis and treatment of
patients remain of vital importance to reduce morbidity and mortality from typhoid fever in
Fiji, a focus on these alone may be insufficient to eliminate transmission. Alongside continued
socio-economic development and expanded access to infrastructure for sanitation, water sup-
plies and handwashing with soap, programmatic vaccination may be amongst interventions
necessary to bring about effective typhoid control in Fiji.
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